{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:14:37Z","timestamp":1790396077002,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1684\/bdc.2011.1341","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"417-424","source":"Crossref","is-referenced-by-count":9,"title":["M\u00e9ningites carcinomateuses des cancers du sein surexprimant HER2 : pour un traitement sp\u00e9cifique ?"],"prefix":"10.1016","volume":"98","author":[{"given":"Maya","family":"Gutierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Lyazidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Brasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Cvitkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Le Scodan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1341_bib0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","article-title":"Neoplastic meningitis","volume":"5","author":"Gleissner","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1684\/bdc.2011.1341_bib0010","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2005.01.131","article-title":"Neoplastic meningitis","volume":"23","author":"Chamberlain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.nrl.0000219732.33321.cc","article-title":"Neoplastic meningitis","volume":"12","author":"Chamberlain","year":"2006","journal-title":"Neurologist"},{"key":"10.1684\/bdc.2011.1341_bib0020","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO;2-4","article-title":"Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen","volume":"77","author":"Fizazi","year":"1996","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0025","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","article-title":"Brain metastases: the HER2 paradigm","volume":"13","author":"Lin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1341_bib0030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/cncr.22041","article-title":"Primary breast cancer phenotypes associated with propensity for central nervous system metastases","volume":"107","author":"Tham","year":"2006","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0035","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/01.pas.0000213306.05811.b9","article-title":"Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5\/6, and overexpress HER2 or EGFR","volume":"30","author":"Hicks","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1684\/bdc.2011.1341_bib0040","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/annonc\/mdi371","article-title":"Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy","volume":"16","author":"Burstein","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0045","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl053","article-title":"Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer","volume":"17","author":"Andre","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1341_bib0055","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0060","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjc.6601970","article-title":"Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer","volume":"91","author":"Clayton","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0065","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2001.19.13.3297","article-title":"Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab","volume":"19","author":"Baculi","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-007-9663-z","article-title":"Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials","volume":"109","author":"Bria","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1684\/bdc.2011.1341_bib0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1684\/bdc.2010.1040","article-title":"Management of metastatic HER2-positive breast cancer: present and future","volume":"97","author":"Guiu","year":"2010","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0080","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","article-title":"Trastuzumab in CSF","volume":"18","author":"Pestalozzi","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1526-8209(11)70432-3","article-title":"Trastuzumab for breast cancer-related carcinomatous meningitis","volume":"2","author":"Robins","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0090","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0095","first-page":"1373","article-title":"Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer","volume":"15","author":"Stemmler","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1684\/bdc.2011.1341_bib0100","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/00006123-199711000-00005","article-title":"Intraventricular immunotoxin therapy for leptomeningeal neoplasia","volume":"41","author":"Laske","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1684\/bdc.2011.1341_bib0105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/bjc.1990.345","article-title":"Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis","volume":"62","author":"Moseley","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1684\/bdc.2011.1341_bib0115","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","article-title":"Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease","volume":"93","author":"Zidan","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0120","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11060-006-9217-y","article-title":"Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma","volume":"81","author":"Antonini","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1684\/bdc.2011.1341_bib0125","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0130","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1341_bib0135","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0140","first-page":"753","article-title":"Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab","volume":"89","author":"Schulz","year":"2004","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2011.1341_bib0145","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1684\/bdc.2011.1341_bib0150","first-page":"111","article-title":"Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration","volume":"284","author":"Bergman","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1684\/bdc.2011.1341_bib0155","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00002371-199903000-00003","article-title":"Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats","volume":"22","author":"Bergman","year":"1999","journal-title":"J Immunother"},{"key":"10.1684\/bdc.2011.1341_bib0160","first-page":"5514","article-title":"Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer","volume":"9","author":"Grossi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1341_bib0165","first-page":"5101","article-title":"A 28-day intrathecal toxicity study with trastutuzumab in nonhuman primates. San Antonio 2009","volume":"118 Suppl","author":"Braen","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1684\/bdc.2011.1341_bib0170","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1470-2045(06)70864-6","article-title":"Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab","volume":"7","author":"Platini","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1341_bib0175","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/CAD.0b013e32830b58b0","article-title":"Intrathecal trastuzumab (herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report","volume":"19","author":"Stemmler","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1684\/bdc.2011.1341_bib0180","first-page":"857","article-title":"Trastuzumab and blood-brain barrier","volume":"94","author":"Platini","year":"2007","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0185","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1341_bib0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1526-8209(11)70419-0","article-title":"Use of intrathecal trastuzumab in a patient with carcinomatous meningitis","volume":"2","author":"Laufman","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.1684\/bdc.2011.1341_bib0195","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","article-title":"High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer","volume":"19","author":"Mir","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115306603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115306603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T17:19:30Z","timestamp":1610817570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115306603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0007455115306603"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1341","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}